JP2006502168A - イソオキサゾールおよびその使用 - Google Patents

イソオキサゾールおよびその使用 Download PDF

Info

Publication number
JP2006502168A
JP2006502168A JP2004534669A JP2004534669A JP2006502168A JP 2006502168 A JP2006502168 A JP 2006502168A JP 2004534669 A JP2004534669 A JP 2004534669A JP 2004534669 A JP2004534669 A JP 2004534669A JP 2006502168 A JP2006502168 A JP 2006502168A
Authority
JP
Japan
Prior art keywords
compound
alkyl
treating
hydrogen
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004534669A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006502168A5 (https=
Inventor
マーク レデボー，
ブライアン レッドフォード，
フランセスコ ジー． サリトゥロ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of JP2006502168A publication Critical patent/JP2006502168A/ja
Publication of JP2006502168A5 publication Critical patent/JP2006502168A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2004534669A 2002-09-06 2003-09-08 イソオキサゾールおよびその使用 Pending JP2006502168A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40881302P 2002-09-06 2002-09-06
PCT/US2003/027903 WO2004022555A1 (en) 2002-09-06 2003-09-08 Isoxazoles and their use in the treatment of ischemic diseases

Publications (2)

Publication Number Publication Date
JP2006502168A true JP2006502168A (ja) 2006-01-19
JP2006502168A5 JP2006502168A5 (https=) 2006-08-24

Family

ID=31978686

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004534669A Pending JP2006502168A (ja) 2002-09-06 2003-09-08 イソオキサゾールおよびその使用

Country Status (5)

Country Link
US (1) US20040132755A1 (https=)
EP (1) EP1546141A1 (https=)
JP (1) JP2006502168A (https=)
AU (1) AU2003270350A1 (https=)
WO (1) WO2004022555A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005320544B2 (en) * 2004-12-28 2011-03-24 Aska Pharmaceutical Co., Ltd. Pyrimidinylisoxazol derivative
ATE527255T1 (de) 2005-12-27 2011-10-15 Hoffmann La Roche Aryl-isoxazol-4-yl-imidazol-derivate
EP2036905B1 (en) 2006-06-28 2012-12-12 ASKA Pharmaceutical Co., Ltd. Pyridylisoxazole derivative
WO2008001929A1 (en) 2006-06-28 2008-01-03 Aska Pharmaceutical Co., Ltd. Treatment agent for inflammatory bowel disease
US8309138B2 (en) 2007-02-16 2012-11-13 Aska Pharmaceutical Co., Ltd. Pharmaceutical composition comprising microparticle oily suspension
MX2009014001A (es) 2007-06-22 2010-01-28 Hoffmann La Roche Derivados de isoxazol-imidazol.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012621A1 (en) * 1999-08-13 2001-02-22 Vertex Pharmaceuticals Incorporated INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003004492A1 (en) * 2001-07-03 2003-01-16 Vertex Pharmaceuticals Incorporated Isoxazolyl-pyrimidines as inhibitors of src and lck protein kinases
US20030207873A1 (en) * 2002-04-10 2003-11-06 Edmund Harrington Inhibitors of Src and other protein kinases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001012621A1 (en) * 1999-08-13 2001-02-22 Vertex Pharmaceuticals Incorporated INHIBITORS OF c-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES

Also Published As

Publication number Publication date
WO2004022555A1 (en) 2004-03-18
EP1546141A1 (en) 2005-06-29
AU2003270350A1 (en) 2004-03-29
US20040132755A1 (en) 2004-07-08

Similar Documents

Publication Publication Date Title
KR102705376B1 (ko) 화학적 화합물
JP4445504B2 (ja) Ｄｐｐ−ｉｖ阻害剤としてのヘキサヒドロピリドイソキノリン
TWI405761B (zh) 適合作為傑納斯激酶（ｊａｎｕｓ ｋｉｎａｓｅ）抑制劑之氮雜吲哚
US9951026B2 (en) Heterocyclic vinyl autotaxin inhibitor compounds
JP2019055974A (ja) ナトリウムチャネルの調節剤として有用なピリドンアミドのプロドラッグ
EP2807160B1 (en) Antifibrotic compounds and uses thereof
BR112014030284B1 (pt) Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
CA3082855A1 (en) 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists
CN117045653A (zh) 与毒性醛相关的疾病和治疗
MX2014015933A (es) Moduladores de la senda del complemento y usos de los mismos.
JP7748545B2 (ja) Ａｈｒアゴニスト
KR20180026390A (ko) 오토탁신 억제제 및 이의 용도
KR20170055531A (ko) 에스지씨 자극제
CA3075705A1 (en) Beta-hydroxy heterocyclic amines and their use in the treatment of hyperglycaemia
WO2019191721A1 (en) Etbr antagonist compounds, compositions, and uses
AU2016349148A1 (en) 1,4-dicarbonyl-piperidyl derivatives
JP2006502168A (ja) イソオキサゾールおよびその使用
CN111630058B (zh) 吡喃葡萄糖基衍生物及其用途
JP4619795B2 (ja) ホスファターゼのインヒビター
EP3472149B1 (en) Heterocyclic prolinamide derivatives
AU2020310296B2 (en) Glucopyranosyl derivatives and their uses
WO2025061048A1 (zh) 甾体化合物及其应用
WO2005100341A1 (ja) ２－アミノピリミジン誘導体
RS55998B1 (sr) Novi anti-malarijski agensi
JP2006502168A5 (https=)

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20060706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060706

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100426

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100507

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100526

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100602

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100625

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100702

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101007